Boston An independent LDT provider

Press releases

January 8, 2025 | REGULATORY

Immunovia AB (Publ) presents Nomination Committee

Read press release
January 2, 2025 | REGULATORY

The exercise period for warrants of series TO 2 begins today

Read press release
December 27, 2024 | REGULATORY

Immunovia announces determined exercise price for warrants series TO 2 and conditionally securing 65% of the warrant programme

Read press release
December 20, 2024

Immunovia discovery study published in top protein research journal

Read press release
December 19, 2024

End of the Year 2024 Letter from Immunovia CEO Jeff Borcherding

Read press release
December 18, 2024

Immunovia CEO and board members announce intention to fully exercise their TO2 warrants

Read press release
December 16, 2024

Immunovia to host a webcast with the opportunity to learn more about the positive clinical validation of its next-generation pancreatic cancer test

Read press release
December 11, 2024

Immunovia announces financial calendar for financial year 2025/2026

Read press release
December 9, 2024

Immunovia announces positive outcome and strong accuracy in the clinical validation of its next-generation test for pancreatic cancer

Read press release
November 28, 2024

Immunovia to present at the Redeye Technology & Life Science Day

Read press release
November 27, 2024 | REGULATORY

Immunovia Publishes Interim Report for January-September 2024

Read press release
November 15, 2024

Immunovia presents model-development study results at meeting of the Collaborative Group of the Americas—Inherited Gastrointestinal Cancers

Read press release
1 2 3 … 30
Home Press releases